GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Neuronetics Inc (NAS:STIM) » Definitions » Beneish M-Score

Neuronetics (Neuronetics) Beneish M-Score

: -2.35 (As of Today)
View and export this data going back to 2018. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.35 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Neuronetics's Beneish M-Score or its related term are showing as below:

STIM' s Beneish M-Score Range Over the Past 10 Years
Min: -2.42   Med: -2.3   Max: 0.05
Current: -2.35

During the past 8 years, the highest Beneish M-Score of Neuronetics was 0.05. The lowest was -2.42. And the median was -2.30.


Neuronetics Beneish M-Score Historical Data

The historical data trend for Neuronetics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuronetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Premium Member Only Premium Member Only Premium Member Only 0.05 -2.03 -2.32 -2.42 -2.35

Neuronetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.42 -2.59 -2.48 -1.99 -2.35

Competitive Comparison

For the Diagnostics & Research subindustry, Neuronetics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuronetics Beneish M-Score Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Neuronetics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Neuronetics's Beneish M-Score falls into.



Neuronetics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Neuronetics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1795+0.528 * 1.0522+0.404 * 1.3607+0.892 * 1.0942+0.115 * 0.8005
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8806+4.679 * -0.034024-0.327 * 1.393
=-2.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $17.84 Mil.
Revenue was 20.314 + 17.884 + 17.61 + 15.54 = $71.35 Mil.
Gross Profit was 15.771 + 11.764 + 12.774 + 11.396 = $51.71 Mil.
Total Current Assets was $93.79 Mil.
Total Assets was $115.83 Mil.
Property, Plant and Equipment(Net PPE) was $4.78 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.01 Mil.
Selling, General, & Admin. Expense(SGA) was $72.74 Mil.
Total Current Liabilities was $19.81 Mil.
Long-Term Debt & Capital Lease Obligation was $61.63 Mil.
Net Income was -5.377 + -9.391 + -4.901 + -10.52 = $-30.19 Mil.
Non Operating Income was 0.894 + 0.664 + 3.592 + 0.64 = $5.79 Mil.
Cash Flow from Operations was 2.133 + -10.124 + -8.834 + -15.213 = $-32.04 Mil.
Total Receivables was $13.82 Mil.
Revenue was 18.198 + 16.498 + 16.329 + 14.181 = $65.21 Mil.
Gross Profit was 13.808 + 12.928 + 12.29 + 10.696 = $49.72 Mil.
Total Current Assets was $98.77 Mil.
Total Assets was $116.88 Mil.
Property, Plant and Equipment(Net PPE) was $5.32 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.65 Mil.
Selling, General, & Admin. Expense(SGA) was $75.50 Mil.
Total Current Liabilities was $33.20 Mil.
Long-Term Debt & Capital Lease Obligation was $25.80 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(17.838 / 71.348) / (13.821 / 65.206)
=0.250014 / 0.211959
=1.1795

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(49.722 / 65.206) / (51.705 / 71.348)
=0.762537 / 0.724687
=1.0522

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (93.793 + 4.782) / 115.831) / (1 - (98.769 + 5.318) / 116.884)
=0.148976 / 0.109485
=1.3607

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=71.348 / 65.206
=1.0942

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.648 / (1.648 + 5.318)) / (2.006 / (2.006 + 4.782))
=0.236578 / 0.295522
=0.8005

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(72.743 / 71.348) / (75.499 / 65.206)
=1.019552 / 1.157854
=0.8806

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((61.629 + 19.812) / 115.831) / ((25.796 + 33.199) / 116.884)
=0.703102 / 0.504731
=1.393

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-30.189 - 5.79 - -32.038) / 115.831
=-0.034024

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Neuronetics has a M-score of -2.35 suggests that the company is unlikely to be a manipulator.


Neuronetics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Neuronetics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuronetics (Neuronetics) Business Description

Traded in Other Exchanges
Address
3222 Phoenixville Pike, Malvern, PA, USA, 19355
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Executives
Keith J Sullivan director, officer: President and CEO C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
William Andrew Macan officer: Sr. VP, GC, CCO and Secretary 24275 KATY FREEWAY, SUITE 600, KATY TX 77494
Stephen Furlong officer: CFO C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Robert Cascella director C/O HOLOGIC, INC., BEDFORD MA 01730
John K Bakewell director C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NO. BILLERICA MA 01862
Cannell Capital Llc 10 percent owner 245 MERIWETHER CIRCLE, ALTA WY 83414
Joseph H Capper director BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Bruce Joseph Shook director 162 CRICKET AVE, ARDMORE PA 19003
Megan Rosengarten director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Sheryl L Conley director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Wilfred E Jaeger director C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Glenn P Muir director C/O HOLOGIC, INC., BEDFORD MA 01730
Gregory Harper officer: VP of Prod. Dev. & Operations C/O NEURONETICS, INC, 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Brian E Farley director 2200 ZANKER ROAD, SUITE F, SAN JOSE CA 95131
Daniel Guthrie officer: Chief Commercial Officer C/O NEURONETICS, INC, 322 PHOENIXVILLE PIKE, MALVERN PA 19355